Navigation Links
Researchers reveal potential treatment for sickle cell disease
Date:11/1/2011

Ann Arbor, Mich. -- A University of Michigan Health System laboratory study reveals a key trigger for producing normal red blood cells that could lead to a new treatment for those with sickle cell disease.

The study, conducted in mice, appears in this week's early edition of the Proceedings of the National Academy of Sciences, and holds promise for preventing the painful episodes and organ damage that are common complications of sickle cell disease.

According to the U-M study, increasing the expression of the proteins, TR2 and TR4, more than doubled the level of fetal hemoglobin produced in sickle cell mice and reduced organ damage.

It's the first time specific proteins have been targeted to prevent a disease, authors say.

"The vast majority of sickle cell disease patients are diagnosed early in childhood when adult hemoglobin normally replaces fetal hemoglobin, but the severity of the disease can differ markedly, correlating most strongly with the level of fetal hemoglobin present in red cells," says pediatrician and lead study author Andrew D. Campbell, M.D., director of the Pediatric Comprehensive Sickle Cell Program at the U-M Cancer Center.

Sickle cell is an inherited blood disorder impacting hundreds of thousands of patients worldwide that causes normal red blood cells to change shape to a crescent moon.

The result is life-long debilitating pain episodes, chronic organ damage and significantly shortened life span. But a small number of sickle cell patients are born with a high enough fetal hemoglobin level to moderate these complications.

The study team, that included pediatric hematologists, cell and developmental biologists and pathology experts at U-M and the University of Tsukuba, Japan, demonstrated a potential method for boosting the fetal hemoglobin levels by modulating TR2/TR4 expression.

"While the average fetal hemoglobin was 7.6 percent in the sickle cell mice, the TR2/TR4 treated sickle cell mice had an average fetal hemoglobin of 18.6 percent," says senior study author James Douglas Engel, Ph.D. , professor and chair of the U-M's Cell and Development Biology Department.

He adds that anemia and red blood cell turnover all improved within the TR2/TR4 mice. Additional studies, including clinical trials, would be requiredto determine if the technique could help humans.

"Currently hydroxyurea is the only FDA approved drug known to increase the levels of fetal hemoglobin within sickle cell disease patients and a substantial number of patients do respond to it," says Campbell, the pediatric hematology oncology specialist. "But the long term consequences for hydroxyurea are unknown, especially in children."


'/>"/>
Contact: Shantell M. Kirkendoll
smkirk@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert  

Related medicine news :

1. Senior citizens as co-researchers to improve urban planning
2. Plant researchers locate transporter used for nicotine metabolism
3. Live-action films of worm sperm help researchers track critical fertility enzymes
4. Moffitt Cancer Center researchers find regulatory T-cell clue to help prevent GVHD
5. Researchers identify potential risk factors for severe altitude sickness
6. Moffitt Cancer Center researchers find more clues to causes of breast cancer
7. Georgetown researchers examine 21-year series of nipple sparing mastectomy cases and find no cancers
8. Medical researchers ID potential new drug target that could stop debilitating effects of MS
9. Researchers develop method to better estimate vaccine coverage
10. Veterinary researchers discover first US strains of hepatitis E virus from rabbits
11. Researchers have found evidence for the existence of a hypnotic state
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers reveal potential treatment for sickle cell disease
(Date:5/27/2016)... ... May 27, 2016 , ... Southland Log Homes ... classic American timber frame barn kits, which can be found on its website at ... historic American barn plans, and they highlight the craftsmanship of timber post and beam ...
(Date:5/27/2016)... , ... May 27, 2016 , ... This campaign aims ... stroke, which we as a society can control and change. , As nearly 795,000 ... every 40 seconds within the United States. Plus, with an estimated 129,000 of these ...
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, 2016 , ... ... bolstered by inspiring human interest stories, which come courtesy of leaders in the nursing ... within the industry, from leading advocates and associations—namely Abilene Christian University. , As ...
(Date:5/26/2016)... ... , ... W.S. Badger Co. Inc ., the maker of certified organic ... Works Award for its use of effective workplace strategies to increase business and employee ... by the Families and Work Institute (FWI) and the Society for Human Resource Management ...
(Date:5/26/2016)... ... 2016 , ... On Memorial Day, Hope For Heroes and USA ... battle for the country. The nonprofit Hope For Heroes partnered with the leading ... independence for disabled military veterans, as well as police, firemen, and EMS professionals across ...
Breaking Medicine News(10 mins):
(Date:5/30/2016)... 30, 2016 LifeScienceIndustryResearch.com adds ... research report with comprehensive information on the therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ... key players involved in the therapeutic development for ...
(Date:5/27/2016)... LONDON , May 27, 2016 ... an innovative biopharma company focused on the highly ... built a substantial pipeline of potential first-in-class or ... which are in development with strategic partners. HCM,s ... the fast-growing domestic market. We expect progress of ...
(Date:5/26/2016)... -- A key trend that will boost ... new treatments. Cardax, a development stage life sciences company, ... is expected to fulfil large unmet medical needs in ... to develop new treatments for osteoarthritis. One such study ... osteoarthritis are being investigated, and early trials of stem-cell ...
Breaking Medicine Technology: